
Lipocine (LPCN) Stock Forecast & Price Target
Lipocine (LPCN) Analyst Ratings
Bulls say
Lipocine Inc. is positioned for potential revenue growth, particularly with the expected regulatory approval and commercialization of its oral testosterone replacement therapy, TLANDO, in Canada, which management anticipates could significantly enhance topline revenue. The development of LPCN 1154, an oral formulation of brexanolone, showcases promising clinical outcomes, including an impressive remission rate of up to 61% by Day 3, suggesting that it may fulfill substantial unmet medical needs in postpartum depression. Furthermore, the exclusive licensing agreement with Verity for TLANDO in the U.S. underscores strategic partnerships that could bolster market presence and contribute positively to the company's financial outlook.
Bears say
Lipocine Inc reported a net loss of $3.2 million in the third quarter of 2025, indicating ongoing financial challenges as the company advances its drug candidates. The upcoming Phase 3 PPD trial, set to report topline data in the second quarter of 2026, presents significant risks, particularly regarding the potential failure of LPCN 1154 in clinical trials and its subsequent ability to secure regulatory approval and commercial success. Additional concerns include the risk of dilution and competitive pressures that could hinder Lipocine's market entry and performance.
This aggregate rating is based on analysts' research of Lipocine and is not a guaranteed prediction by Public.com or investment advice.
Lipocine (LPCN) Analyst Forecast & Price Prediction
Start investing in Lipocine (LPCN)
Order type
Buy in
Order amount
Est. shares
0 shares